Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Shenzhen, China, July 26, 2024 (GLOBE NEWSWIRE) -- On July 25th, Geekvape officially released its first Carbon Neutrality Action Report (referred to as the “Action Report”), committing to achieving...
-
Dublin, July 26, 2024 (GLOBE NEWSWIRE) -- The "Critical Materials Shaping Energy Transition" report has been added to ResearchAndMarkets.com's offering.The global energy transition will require a...
-
Media relations:Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com Capgemini H1 2024 results H1...
-
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) announces that it has been requested by OTC...
-
Clermont-Ferrand – July 24, 2024 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Segment operating income of 13.2% of sales in the first half of 2024. Strong free cash flow generation. Full-year...
-
VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“Alaska Energy Metals” or the “Company”) today announced that all matters...
-
Toronto, July 18, 2024 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) an exploration company with a portfolio of...
-
Toronto, July 08, 2024 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) an exploration company with a portfolio of...
-
VANCOUVER, British Columbia, June 24, 2024 (GLOBE NEWSWIRE) -- NorthWest Copper (“NorthWest” or “the Company”) (TSX-V: NWST) is pleased to report that positive metallurgical results have been...
-
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2...